CSL Invests $235 Million In Manufacturing Facility For Late-stage Development In Australia
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - CSL Limited announced July 16 that it will invest $235 million to expand its manufacturing site in Broadmeadows, Australia to create Victoria's first large-scale biotechnology facility for late-stage development of new therapies for cancer, bleeding disorders, inflammation and infections
You may also be interested in...
U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine
PERTH, Australia - U.S. FDA's Center for Biologics issued an Untitled Letter June 24 to CSL Biotherapies for deviations from current good manufacturing practices at its manufacturing plant in the Australian state of Victoria
Lilly And Queensland Government Invest In First-ever Australian Biotech VC Fund
PERTH, Australia - Eli Lilly and the Queensland government have formed a $250 million venture capital fund to invest in Australia's biotech sector, Queensland Premier Anna Bligh announced May 20
Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
PERTH, Australia - As part of the new federal budget announced May 11, Medicines Australia has negotiated price-saving measures with the Australian government that will cut prices on off-patent medicines in exchange for an assurance from the government that innovative prices on drugs will not be cut for four years